logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11173173 B1

PDFFull Text
Date of Patent:
Nov. 16, 2021

Filed:

Jul. 28, 2016

Methods for treating chemoresistant cancer-initiating cells

Applicants:

University of Connecticut, Farmington, CT (US);

Stowers Institute for Medical Research, Kansas City, MO (US);

University of Kansas, Lawrence, KS (US);

Inventors:

Rajeswari Kasi, Windsor, CT (US);

Linheng Li, Kansas City, MO (US);

Xiuling Lu, Storrs, CT (US);

John M. Perry, Kansas City, MO (US);

Gurusingham Sitta Sittampalam, Fishers, IN (US);

Anuradha Roy, Kansas City, MO (US);

Xi C. He, Kansas City, MO (US);

Assignees:

UNIVERSITY OF CONNECTICUT, Farmington, CT (US);

UNIVERSITY OF KANSAS, Lawrence, KS (US);

STOWERS INSTITUTE FOR MEDICAL RESEARCH, Kansas City, MO (US);

Attorney:

McDonnell Boehnen Hulbert & Berghoff LLP

Primary Examiner:

Jessica Worsham

Int. Cl.
CPC ...
A61K 9/51 (2006.01); A61K 31/704 (2006.01); A61K 31/513 (2006.01); A61K 31/136 (2006.01); A61K 31/4745 (2006.01); A61K 45/06 (2006.01); A61K 31/573 (2006.01); A61K 9/00 (2006.01); A61K 31/18 (2006.01); A61K 31/475 (2006.01); A61K 31/519 (2006.01); A61K 31/7076 (2006.01); A61K 31/708 (2006.01); A61K 31/337 (2006.01); A61K 33/242 (2019.01); A61K 33/243 (2019.01); A61P 35/02 (2006.01);
U.S. Cl.
CPC ...
A61K 31/704 (2013.01); A61K 9/0019 (2013.01); A61K 9/5138 (2013.01); A61K 9/5146 (2013.01); A61K 31/136 (2013.01); A61K 31/18 (2013.01); A61K 31/337 (2013.01); A61K 31/475 (2013.01); A61K 31/4745 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/573 (2013.01); A61K 31/708 (2013.01); A61K 31/7076 (2013.01); A61K 33/242 (2019.01); A61K 33/243 (2019.01); A61K 45/06 (2013.01); A61P 35/02 (2018.01); A61K 9/0009 (2013.01);
Abstract

The disclosure provides methods of treating cancer by selectively inhibiting p-S-β-catenin, p-T-β-catenin, p-T-β-catenin, and/or p-S-β-catenin production and/or activity. Such methods also and/or limit cancer-initiating cells.

Find Patent Forward Citations

Loading…